(Press-News.org) Subscribe to UCSF News
A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new guidelines.
Type 2 diabetes (T2D), a condition in which the body can’t use insulin to clear sugar from the bloodstream, affects 1 in 10 Americans. It comes with grave health risks, including cardiovascular and kidney disease.
The study assessed medications that patients received within a year of T2D diagnosis. During the period under review — 2014 to 2022 — groups like the American Diabetes Association and the American Heart Association began encouraging the use of newer medications over some older, less effective ones.
The analysis, which is based on more than 40,000 records from the University of California Health Data Warehouse, found some encouraging results.
The use of sodium-glucose cotransporter 2 (SGLT2) inhibitors or glucagon-like peptide 1 (GLP-1) receptor agonists — two newer categories of drugs — increased, particularly among patients with cardiovascular or kidney disease.
Meanwhile, the use of sulfonylureas — a category of diabetes drug with severe side effects, now seen as a last resort in treatment — declined. And the use of metformin and insulins, the classic medications for diabetes, declined slightly.
Still, by 2022, just 20% T2D patients were receiving GLP-1 drugs within a year of diagnosis, and less than 15% of patients were receiving SGLT2 drugs — reflecting a gap between what the professional guidelines recommend and the care that patients are receiving.
The researchers gave several reasons for why this might be. One is that GLP-1 drugs, like Wegovy and Ozempic, are expensive, and insurance doesn’t always cover them. Another is that not every provider knows that leading organizations recommend prescribing GLP-1 and SGLT2 drugs, like Jardiance or Farxiga, for T2D from the moment of diagnosis.
“Some of the most devastating consequences of diabetes come from its effects on the heart and kidney, and thankfully, we now have drugs that target those effects head on,” said Jonathan Watanabe, PharmD, MS, PhD, the senior author of the study. “But to maximize the benefit for the many hundreds of thousands of patients in the U.S., we need to increase access to these drugs and make sure that clinicians understand just how beneficial they are.”
Publication: Journal of Diabetes
Other Researchers: William Hou of UC Irvine; Katherine R. Tuttle, MD, of University of Washington; Weining Shen, PhD, of UC Irvine, and Andrew Rekes, MD, of UC Irvine.
About UCSF: The University of California, San Francisco (UCSF) is exclusively focused on the health sciences and is dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. UCSF Health, which serves as UCSF's primary academic medical center, includes top-ranked specialty hospitals and other clinical programs, and has affiliations throughout the Bay Area. UCSF School of Medicine also has a regional campus in Fresno. Learn more at ucsf.edu, or see our Fact Sheet.
###
Follow UCSF
ucsf.edu | Facebook.com/ucsf | YouTube.com/ucsf
END
The most effective diabetes drugs don't reach enough patients yet
2025-07-01
ELSE PRESS RELEASES FROM THIS DATE:
Breast cancer risk in younger women may be influenced by hormone therapy
2025-06-30
Scientists at the National Institutes of Health (NIH) have found that two common types of hormone therapy may alter breast cancer risk in women before age 55. Researchers discovered that women treated with unopposed estrogen hormone therapy (E-HT) were less likely to develop the disease than those who did not use hormone therapy. They also found that women treated with estrogen plus progestin hormone therapy (EP-HT) were more likely to develop breast cancer than women who did not use hormone therapy. Together, these results could help to guide clinical recommendations for hormone therapy use among younger women.
The two hormone therapies analyzed in the study are ...
Strategies for staying smoke-free after rehab
2025-06-30
For people recovering from substance use disorders, quitting smoking remains one of the most difficult—but most crucial—steps toward long-term health.
New research from Flinders University reveals that providing consistent support and access to a range of nicotine replacement therapies (NRTs) can help people in recovery take that vital step.
A first-of-its-kind trial to compare vapes with combination nicotine replacement therapy (cNRT) - patches, gum, and lozenges - in people leaving smoke-free ...
Commentary questions the potential benefit of levothyroxine treatment of mild hypothyroidism during pregnancy
2025-06-30
(Boston)—While severe maternal hypothyroidism (low thyroid hormone levels) in pregnancy is known to increase risks of adverse pregnancy outcomes, it is unclear whether mild (subclinical) hypothyroidism causes similarly adverse pregnancy complications. It is also not clear whether maternal hypothyroidism in pregnancy increases risks of gestational diabetes.
A new study in the journal Lancet Diabetes and Endocrinology (Osinga et al “Association of gestational thyroid function and thyroid ...
Study projects over 14 million preventable deaths by 2030 if USAID defunding continues
2025-06-30
A new study published in The Lancet has raised urgent concerns about the global health consequences of recent cuts to U.S. foreign aid. The study, coordinated by researchers from the Barcelona Institute for Global Health (ISGlobal), together with the Institute of Collective Health of the Federal University of Bahia (ISC-UFBA), the University of California Los Angeles (UCLA), and the Manhiça Centre for Health Research (CISM), among others, estimates that 91 million deaths were prevented between 2001 and 2021 in low- and middle-income countries (LMICs) thanks to programs supported by the United States ...
New study reveals 33% gap in transplant access for UK’s poorest children
2025-06-30
(Tuesday 1 July 2025, London, United Kingdom) New research, presented at the ESOT Congress 2025, reveals persistent inequalities in children’s access to life-saving kidney transplants across the UK. The study highlights how ethnicity, socioeconomic status, and gender significantly influence a child's likelihood of receiving a transplant.1
Researchers from the University of Bristol analysed national data from the UK Renal Registry and NHS Blood & Transplant, focusing on patients under 18 years who started kidney replacement therapy between 1996 and 2020.2 Their findings reveal concerning disparities ...
Dysregulated epigenetic memory in early embryos offers new clues to the inheritance of polycystic ovary syndrome (PCOS)
2025-06-30
(Paris, France, Tuesday, 1 July 2025) Novel research presented today at the 41st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) has found that embryos from women with polycystic ovary syndrome (PCOS) carry a distinctive ‘epigenetic memory’ that could explain why the condition often runs in families.[1]
PCOS is a common hormonal disorder affecting an estimated 1 in 10 women of reproductive age worldwide.[2] It is characterised by irregular menstrual cycles, excess levels of androgens (male hormones) and the presence of multiple cysts on the ovaries.[3] While it is recognised as a leading ...
IVF and IUI pregnancy rates remain stable across Europe, despite an increasing uptake of single embryo transfer
2025-06-30
(Paris, France, Tuesday, 1 July 2025) Fewer in vitro fertilisation (IVF) and intrauterine insemination (IUI) cycles were reported in Europe in 20202, but clinical pregnancy rates remained stable, according to data presented at the 41st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) [1].
Preliminary data from the ESHRE European IVF Monitoring (EIM) Consortium [2] reveals a steady and progressive rise in the use of Assisted Reproductive Technology (ART). In 2022, a total of 960,347 ART treatment cycles were reported by 1,371 clinics across 39 European countries, a 15.6% reduction from the 1,137,177 cycles reported in 2021 [3].
Of ...
It takes a village: Chimpanzee babies do better when their moms have social connections
2025-06-30
DURHAM, N.C. — In chimpanzee communities, strong social ties can be a matter of life and death not just for the adults who form them, but for their kids, too.
A new federally-funded study of wild eastern chimpanzees (Pan troglodytes schweinfurthii) from Gombe National Park shows that female chimpanzees who were more socially integrated with other females in the year before giving birth were more likely to raise surviving offspring.
The findings, published online on June 18 in iScience, show that these survival benefits hold for females ...
From lab to market: how renewable polymers could transform medicine
2025-06-30
In recent years, scientists have been exploring the use of renewable polymers derived from natural sources. Materials such as vegetable cellulose, bacterial cellulose, chitosan, and starch offer attractive properties for biomedical applications, especially in controlled drug release systems and regenerative medicine. However, despite their potential, many of these polymers still face significant challenges in reaching commercialization.
The study conducted by Lopes et al. points out that despite advances, only a few natural polymers have become available on the market. The research emphasizes the importance ...
Striking increase in obesity observed among youth between 2011 and 2023
2025-06-30
Embargoed for release until 5:00 p.m. ET on Monday 30 June 2025
Follow @Annalsofim on X, Facebook, Instagram, threads, and Linkedin
Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of information. This information is under strict embargo and by taking it into possession, media representatives are committing to the terms of the embargo not only on their own behalf, ...